Reaction
Cutaneous Lymphoma reporting signals
As of the last recalculation, Cutaneous Lymphoma appears in 200 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is BARICITINIB (PRR 89.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Baricitinib | 8 | 89.9 | 90.0 |
| Polatuzumab Vedotin | 5 | 54.7 | 54.7 |
| Brentuximab Vedotin | 4 | 41.4 | 41.4 |
| Ixekizumab | 11 | 32.7 | 32.7 |